Research and Markets has announced the addition of the "Anterior Uveitis - Pipeline Review, H2 2016" report to their offering.
Anterior Uveitis pipeline therapeutics constitutes close to 6 molecules
Out of which approximately 6 molecules are developed by Companies. Our latest report Anterior Uveitis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Anterior Uveitis Anterior uveitis is an inflammation of the middle layer of the eye, which includes the iris (colored part of the eye) and ciliary body. Symptoms include a red, sore and inflamed eye, blurring of vision, sensitivity to light and a small pupil. The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 2 respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/4f2w46/anterior_uveitis
View source version on businesswire.com: http://www.businesswire.com/news/home/20161012005802/en/Business Wire
Last updated on: 12/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.